CSL Behring and Bayer Extend Agreement Related to Hemophilia

Global distribution of Helixate ecombinant coagulation Factor VIII will run through through 2017.!--h2>

CSL Behring reached an agreement with Bayer HealthCare to continue the supply and distribution of a therapy for the treatment of hemophilia A. Bayer will provide Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.

Additionally, Bayer was granted a license to intellectual property related to recombinant FVIII. At the same time, the companies settled outstanding litigation relating to the supply of recombinant Factor VIII.